E Elhassadi1,2, R Flavin3,4, P Browne5,3, E Conneally5,3, P Hayden5,3, F Quinn6, E Higgins5, E Vandenberghe5,3. 1. Haematology Department, St James Hospital, Dublin, Ireland. ezzat.elhassadi@hse.ie. 2. Academic Department of Haematology, Trinity College Dublin, Dublin, Ireland. ezzat.elhassadi@hse.ie. 3. Academic Department of Haematology, Trinity College Dublin, Dublin, Ireland. 4. Histopathology Department, St. James's Hospital, Dublin, Ireland. 5. Haematology Department, St James Hospital, Dublin, Ireland. 6. Cancer Molecular Diagnostic Department, St. James's Hospital, Dublin, Ireland.
Abstract
PURPOSE: Retrospective study to evaluate the outcome of patients with transformed follicular lymphoma (tFL) treated with rituximab-containing chemotherapy and consolidation. PATIENTS AND METHODS: Patients diagnosed with tFL from 2003 to 2013 treated with consolidation therapy with last follow-up in December 2015 were identified from the institutional lymphoma database and included in this study. Data collected included age, gender, stage, interval to tFL diagnosis, R-IPI score, histological diagnosis and therapy. The treatment algorithm used was stratified for age, performance status (PS) and sibling donor availability using R-chemotherapy induction followed by consolidation with allogeneic stem cell transplant (SCT), autologous SCT, Zevalin or rituximab maintenance (RM). Patients with B-cell lymphoma with features intermediate between diffuse large B-cell lymphoma and Burkitt's lymphoma (BCL-U), with FISH-proven t(14;18) and t(8;14) and their variants were excluded. RESULTS: Four hundred patients were diagnosed with FL of whom 26 (7%) developed histologically proven tFL. The group was predominantly male (73%) with a median age at transformation of 53 (range 27-72) years and 85% presented with stage III/IV disease. Thirteen (50%) patients presented with de novo tFL and the remainder had previously diagnosed FL, with a median time to transformation of 5.7 (range 1-15) years. The median follow-up time from tFL diagnosis to December 2015 is 8 (range 4-14) years. All patients received immuno-chemotherapy achieving an overall response rate (ORR) of 100%. Fourteen (54%), patients were transplant eligible and based on donor availability, six had an auto-SCT only, five had an allo-SCT only and three had a matched unrelated allo-SCT for a post-auto-SCT relapse. The 12 patients (46%) who were not transplant eligible were consolidated with rituximab maintenance (RM) in nine (35%) and Zevalin in three (11%) cases. The overall survival (OS) and progression-free survival (PFS) for the series at 5 years were, 92 and 73%, respectively. CONCLUSION: This consecutively treated series of 26 patients with tFL have had a better outcome than expected which may be due to the use of rituximab-chemotherapy and a consolidation strategy based on age, PS and availability of a sibling donor.
PURPOSE: Retrospective study to evaluate the outcome of patients with transformed follicular lymphoma (tFL) treated with rituximab-containing chemotherapy and consolidation. PATIENTS AND METHODS: Patients diagnosed with tFL from 2003 to 2013 treated with consolidation therapy with last follow-up in December 2015 were identified from the institutional lymphoma database and included in this study. Data collected included age, gender, stage, interval to tFL diagnosis, R-IPI score, histological diagnosis and therapy. The treatment algorithm used was stratified for age, performance status (PS) and sibling donor availability using R-chemotherapy induction followed by consolidation with allogeneic stem cell transplant (SCT), autologous SCT, Zevalin or rituximab maintenance (RM). Patients with B-cell lymphoma with features intermediate between diffuse large B-cell lymphoma and Burkitt's lymphoma (BCL-U), with FISH-proven t(14;18) and t(8;14) and their variants were excluded. RESULTS: Four hundred patients were diagnosed with FL of whom 26 (7%) developed histologically proven tFL. The group was predominantly male (73%) with a median age at transformation of 53 (range 27-72) years and 85% presented with stage III/IV disease. Thirteen (50%) patients presented with de novo tFL and the remainder had previously diagnosed FL, with a median time to transformation of 5.7 (range 1-15) years. The median follow-up time from tFL diagnosis to December 2015 is 8 (range 4-14) years. All patients received immuno-chemotherapy achieving an overall response rate (ORR) of 100%. Fourteen (54%), patients were transplant eligible and based on donor availability, six had an auto-SCT only, five had an allo-SCT only and three had a matched unrelated allo-SCT for a post-auto-SCT relapse. The 12 patients (46%) who were not transplant eligible were consolidated with rituximab maintenance (RM) in nine (35%) and Zevalin in three (11%) cases. The overall survival (OS) and progression-free survival (PFS) for the series at 5 years were, 92 and 73%, respectively. CONCLUSION: This consecutively treated series of 26 patients with tFL have had a better outcome than expected which may be due to the use of rituximab-chemotherapy and a consolidation strategy based on age, PS and availability of a sibling donor.
Authors: Wolfgang Hiddemann; Michael Kneba; Martin Dreyling; Norbert Schmitz; Eva Lengfelder; Rudolf Schmits; Marcel Reiser; Bernd Metzner; Harriet Harder; Susanna Hegewisch-Becker; Thomas Fischer; Martin Kropff; Hans-Edgar Reis; Mathias Freund; Bernhard Wörmann; Roland Fuchs; Manfred Planker; Jörg Schimke; Hartmut Eimermacher; Lorenz Trümper; Ali Aldaoud; Reza Parwaresch; Michael Unterhalt Journal: Blood Date: 2005-08-25 Impact factor: 22.113
Authors: K M Ramadan; J M Connors; A J Al-Tourah; K W Song; R D Gascoyne; M J Barnett; T J Nevill; J D Shepherd; S H Nantel; H J Sutherland; D L Forrest; D E Hogge; J C Lavoie; Y R Abou-Mourad; M Chhanabhai; N J Voss; R R Brinkman; C A Smith; C L Toze Journal: Bone Marrow Transplant Date: 2008-08-11 Impact factor: 5.483
Authors: Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl Journal: J Clin Oncol Date: 2007-01-22 Impact factor: 44.544
Authors: Robert Marcus; Kevin Imrie; Andrew Belch; David Cunningham; Eduardo Flores; John Catalano; Philippe Solal-Celigny; Fritz Offner; Jan Walewski; Joäo Raposo; Andrew Jack; Paul Smith Journal: Blood Date: 2004-10-19 Impact factor: 22.113
Authors: Marianne B Eide; Grete F Lauritzsen; Gunnar Kvalheim; Arne Kolstad; Unn M Fagerli; Martin Maisenhölder; Bjørn Østenstad; Øystein Fluge; Jan Delabie; Harald Aarset; Knut Liestøl; Harald Holte Journal: Br J Haematol Date: 2011-01-17 Impact factor: 6.998
Authors: J J M van Dongen; A W Langerak; M Brüggemann; P A S Evans; M Hummel; F L Lavender; E Delabesse; F Davi; E Schuuring; R García-Sanz; J H J M van Krieken; J Droese; D González; C Bastard; H E White; M Spaargaren; M González; A Parreira; J L Smith; G J Morgan; M Kneba; E A Macintyre Journal: Leukemia Date: 2003-12 Impact factor: 11.528
Authors: Diego Villa; Michael Crump; Tony Panzarella; Kerry J Savage; Cynthia L Toze; Douglas A Stewart; David A MacDonald; Rena Buckstein; Christina Lee; Mohsen Alzahrani; Morel Rubinger; Ronan Foley; Anargyros Xenocostas; Mitchell Sabloff; Alexandra Muccilli; Neil Chua; Felix Couture; Jean-François Larouche; Sandra Cohen; Joseph M Connors; Kimberley Ambler; Abdulwahab Al-Tourah; Khaled M Ramadan; John Kuruvilla Journal: J Clin Oncol Date: 2013-02-11 Impact factor: 44.544
Authors: Abdulwahab J Al-Tourah; Karamjit K Gill; Mukesh Chhanabhai; Paul J Hoskins; Richard J Klasa; Kerry J Savage; Laurie H Sehn; Tamara N Shenkier; Randy D Gascoyne; Joseph M Connors Journal: J Clin Oncol Date: 2008-10-06 Impact factor: 44.544
Authors: Andrew R Rezvani; Barry Storer; Michael Maris; Mohamed L Sorror; Edward Agura; Richard T Maziarz; James C Wade; Thomas Chauncey; Stephen J Forman; Thoralf Lange; Judith Shizuru; Amelia Langston; Michael A Pulsipher; Brenda M Sandmaier; Rainer Storb; David G Maloney Journal: J Clin Oncol Date: 2007-12-03 Impact factor: 44.544